Brief: Mayne Pharma Anticipates FY25 Underlying EBITDA In Range Of A$47 Million To A$51 Million

Mayne Pharma

22/04/2025 02:33

April 22 (Reuters) - Mayne Pharma Group Ltd MYX.AX:

IN FY25, ANTICIPATES UNDERLYING EBITDA IN RANGE OF A$47 MILLION TO A$51 MILLION

9-MONTHS UNAUDITED UNDERLYING EBITDA A$28.6 MILLION

SIGNS AGREEMENT WITH SOL-GEL TECHNOLOGIES

9-MONTHS REVENUE A$300 MILLION

TERMS OF DEAL ARE US$10 MILLION IN CASH AT CLOSING AND AN ADDITIONAL US$6 MILLION IN CASH SIX MONTHS THEREAFTER

Further company coverage: MYX.AX

 ((Reuters.Briefs@thomsonreuters.com;))